Achieve Life Sciences (ACHV) Interest Expenses (2011 - 2026)
Achieve Life Sciences' (ACHV) quarterly Interest Expenses came in at $274000.0 in Q1 2026, up 48.11% YoY from $185000.0 in Q1 2025, and up 1726.67% on a QoQ basis from $15000.0 in Q4 2025.
Achieve Life Sciences (ACHV) Interest Expenses (2011 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 16 years of Interest Expenses data on file, last reported at $274000.0 in Q1 2026.
- Quarterly Interest Expenses rose 48.11% year-over-year to $274000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $672000.0 (down 56.7% YoY) and the FY2025 annual result came in at $1.4 million, down 35.78% from the prior year.
- Interest Expenses advanced to $274000.0 in Q1 2026, from $15000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $2.8 million in Q4 2023 to a low of $15000.0 in Q4 2025.
- A 5-year average of $641117.6 and a median of $404000.0 in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses soared 11526.67% — and 2024, when it tumbled 92.99%.
- Tracing ACHV's Interest Expenses over 5 years: stood at $1.7 million in 2022, then jumped by 61.12% to $2.8 million in 2023, then plunged by 92.99% to $197000.0 in 2024, then sank by 92.39% to $15000.0 in 2025, then surged by 1726.67% to $274000.0 in 2026.
- The last three Interest Expenses figures came in at $274000.0 (Q1 2026), $15000.0 (Q4 2025), and $192000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | 277,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 277,000.00 |
| Jun 30, 2026 | 277,000.00 |
| Mar 31, 2026 | 274,000.00 |
| Mar 31, 2026 | 274,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2025 | 192,000.00 |
| Sep 30, 2025 | 192,000.00 |
| Jun 30, 2025 | 191,000.00 |
| Jun 30, 2025 | 191,000.00 |
| Mar 31, 2025 | 185,000.00 |
| Mar 31, 2025 | 185,000.00 |
| Dec 31, 2024 | 197,000.00 |
| Dec 31, 2024 | 197,000.00 |
| Sep 30, 2024 | 366,000.00 |
| Sep 30, 2024 | 366,000.00 |
| Jun 30, 2024 | 804,000.00 |
| Jun 30, 2024 | 804,000.00 |
| Mar 31, 2024 | 813,000.00 |
| Mar 31, 2024 | 813,000.00 |